Thomas Reed

A phase I open-label study of Ad-RTS-hIL-12, an adenoviral vector engineered to express hIL-12 under the control of an oral activator ligand, in subjects with unresectable stage III/IV melanoma.

G. Linette, J. Nemunaitis, H. Youssoufian, 2013 .